Companies in #High-Grade Glioma
Found 1 company operating in this sector.
NeOnc Technologies Holdings is a clinical-stage biopharmaceutical company focused on treatments for intracranial malignancies. Its lead candidate NEO100, a purified form of perillyl alcohol delivered intranasally, is in Phase 2a development for recurrent IDH1-mutant high-grade glioma, with topline data expected in August 2026; NEO212, a covalent conjugate of temozolomide and perillyl alcohol, is in Phase 1/2 development for primary and secondary brain cancers including meningioma and glioblastoma. The company was founded by neurosurgeon-scientist Thomas C. Chen and is headquartered in Calabasas, California.